Hemodynamic Phenomenon or Geometric Discrepancy?
The recent study by Li et al. (1) has several limitations. The absence of information on functional capacities, symptoms, preoperative pressure data, or left ventricular (LV) function indices limits the significance of the data.
Perioperative mortality increases when pulmonary artery (PA) pressures exceed 60 mm Hg, which is the cutoff in risk-stratification systems like the Euroscore. A cutoff of 40 mm Hg overestimates the incidence of severe pulmonary hypertension (PHT). Significantly, 15 of 40 patients with prosthesispatient mismatch (PPM) had postoperative atrial fibrillation (AF). The difference in mean gradients between the PPM and non-PPM groups is merely statistical, but insignificant. The investigators suggest a "simple" strategy of implanting a prosthesis to obtain an indexed effective orifice area (EOA) [ Twenty-one of 32 patients with preoperative PHT had PPM. In essence, the smallest valves were implanted in those with large BSAs and preoperative PHT. Naturally, many patients would have residual PHT. Could the investigators have actually undersized the prosthesis in many patients?
Native annular diameter places a major restriction on the maximum implantable prosthesis size. Problems with disproportionately large mitral prostheses include LV outflow obstruction, restriction of prosthetic mobility, circumflex artery and conduction system injury. Complications like atrioventricular groove dehiscence and ventricular rupture with large valves are every surgeon's nightmare. A murine annulus will not take an elephantine prosthesis! 
REPLY
We thank Dr. Shanmugam for his interest in our study (1) . Most of the limitations he raises have been discussed in detail in our report. We have never suggested that a cutoff of 40 mm Hg was equivalent to severe pulmonary hypertension. Nonetheless, as we have also alluded to in our study, such levels of pulmonary pressures, equivalent to mild/moderate pulmonary hypertension, have been associated with significantly worse outcomes. Moreover, the fact that such levels of pressure would persist in patients with prosthesis-patient mismatch (PPM), whereas they would regress in most patients without PPM, indeed confirms that levels above 40 mm Hg are clearly abnormal.
The indexed effective orifice area (EOA) is a physiological parameter that relates to the intrinsic hemodynamic performance of the prosthesis and has nothing to do with valve annular diameters. The threshold value of 1.2 cm 2 /m 2 was chosen to identify PPM because it was the most discriminative value to identify patients with persisting pulmonary artery hypertension after mitral valve replacement (MVR), and it is consistent with previous in vitro and in vivo studies on mitral PPM. As we have emphasized, the pressure gradient is a much less appropriate parameter with which to assess the consequences of PPM, especially in the mitral position, because it is highly influenced by chronotropic conditions and because mitral flow tends to decrease when pulmonary resistances are increased.
The statement that "the minimum absolute valve EOA of any size-23 prosthesis is 2.54 cm 2 " denotes a gross misunderstanding of valve prosthesis physiology and is equivalent to saying that all prostheses of a given labeled size would have similar hemodynamic performance. Indeed, it is well known that labeled sizes have no relevance to valve hemodynamics and that they grossly overestimate the actual EOA, which may vary from one type of prosthesis to another. In this context, it is interesting to note that the normal reference values of EOA for 27-mm mitral prostheses range from 1.6 to 2.2 cm 2 (2). Hence, it is not surprising that PPM defined as an indexed EOA Յ1.2 cm 2 /m 2 can be a frequent occurrence in patients undergoing MVR.
We agree with Dr. Shanmugam that the prevention of PPM in the mitral position is a particularly demanding challenge for the surgeon and that there are not as many options as in the aortic position. Nonetheless, and as we have shown, it is not a rare occurrence and definitely warrants further documentation. Our results also provide impetus for the development of better performing mitral prostheses.
